Biocorrx (OTCMKTS:BICX – Get Free Report) is projected to issue its results on Tuesday, November 17th. Analysts expect Biocorrx to announce earnings of ($0.05) per share and revenue of $0.25 million for the quarter.
Biocorrx (OTCMKTS:BICX – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.02. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.24 million.
Biocorrx Price Performance
BICX stock opened at $0.21 on Monday. The stock has a market capitalization of $6.47 million, a P/E ratio of -1.76 and a beta of 0.07. Biocorrx has a 1-year low of $0.15 and a 1-year high of $1.28. The business has a fifty day moving average price of $0.22 and a 200-day moving average price of $0.31.
Biocorrx Company Profile
BioCorRx, Inc. is a healthcare company focused on substance-use-disorder treatment and related products. Its BioCorRx Recovery Program is an outpatient approach that combines medication-assisted treatment with counseling and ongoing support for people seeking treatment for alcohol or opioid dependence. The company has also pursued pharmaceutical products intended to support addiction treatment, including long-acting formulations. Its business includes developing treatment offerings and working to make them available through healthcare providers.
Read More
- Five stocks we like better than Biocorrx
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Biocorrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocorrx and related companies with MarketBeat.com's FREE daily email newsletter.
